The Central venous catheter market is estimated to be valued at USD 2.36 Bn in 2024 and is expected to exhibit a CAGR of 6.8% over the forecast period (2024-2031). The rising adoption of multilumen catheters and antibacterial coated central venous catheters are expected to fuel the market growth.
Market Dynamics:
The growth of the global central venous catheter market is driven by the increasing incidence of chronic diseases such as cancer and rising number of surgical procedures performed worldwide. According to the American Cancer Society, 1.9 million new cancer cases are diagnosed in the U.S. annually. Central venous catheters play a crucial role in the administration of chemotherapy drugs and nutrition therapies in cancer patients. Moreover, central venous access devices are routinely used during surgical interventions for fluid administration, blood draws, and administration of medications. The rising geriatric population is also contributing to market growth as the elderly are more prone to chronic illnesses. However, risks associated with central venous catheters such as bloodstream infections and thrombosis may hamper the market growth over the forecast period.
Increase in Number of Surgical Procedures Requiring Central Venous Access is Driving the Market Growth
The number of surgical procedures that require central venous access such as chemotherapy, total parenteral nutrition, and blood sampling have seen a steady rise over the past few years. Central venous catheters are widely used in such procedures as they provide reliable long-term vascular access. With the rising disease burden of cancer and other chronic illnesses worldwide, the demand for surgical intervention for treatment and management of such diseases has significantly increased. This has directly contributed to the increased adoption of central venous catheters for efficient drug delivery and fluid administration during such surgical procedures.
Growing Prevalence of Chronic Diseases Needing Intravenous Therapy is Fueling Market Growth
Central venous catheters play a vital role in the long-term intravenous management of many chronic illnesses including cancer, diabetes, gastrointestinal diseases, and kidney ailments. The rising prevalence of such chronic diseases drives the need for intravenous drug delivery and fluid therapy over extended periods, increasing the demand for central venous catheters. According to the World Health Organization (WHO), chronic diseases account for over 60% of global deaths annually. This translates to a growing patient pool requiring long-term intravenous therapy and central line placement, propelling the central venous catheter market.
Shortage of Skilled Personnel for Central Line Placement and Management Hampers Adoption
Correct insertion technique and strict maintenance protocols are essential to prevent central line complications like malpositioning, obstruction, and infections. However, the lack of adequate training and competence among healthcare workers in central line placement and sustained line care is a major concern. The complex nature of central line insertion requires experienced professionals with surgical skills to minimize risks. But many hospitals, especially in low and middle-income countries, face shortages of skilled personnel for central venous access device handling. This acts as a constraint on the central venous catheter market development in such regions.
Risk of Bloodstream Infections Associated with Central Lines Poses Major Challenge
One of the major restraints negatively impacting the growth of the central venous catheter market is the risk of central line-associated bloodstream infections (CLABSI). Central venous catheters placed for long-term intravenous access can become a direct entry point for pathogens into the bloodstream. This makes patients susceptible to life-threatening infections. Avoiding CLABSIs requires strict adherence to sterilization and placement protocols which increase costs for healthcare facilities. Catheter contamination and infection also lead to patient discomfort, longer hospital stays, and higher treatment costs. This reduces the attractiveness of central lines and hinders the overall market expansion.
Advancements in Catheter Designs for Improved Safety and Efficacy Create Opportunities
Constant research and development activities in industrialized nations are driving innovations in central line designs. Many players are introducing next-generation catheter models embedded with anti-microbial coatings, enhanced anchoring mechanisms, and radiopaque markers for image-guided positioning. Such technological advancements are assisting in mitigating complications like movement, kinking, and infections. They also enable accuracy, ease of placement, and reliable operation. The introduction of advanced product varieties catering to diverse clinical needs is boosting sales prospects across the market.
Rising Demand for Ambulatory and Home Care Hemodialysis Expands Prospects
The popularity of ambulatory and home-based hemodialysis as alternatives to hospital-based renal replacement therapies is witnessing strong growth. Their increasing acceptance is fueled by patient preference for convenience and quality of life improvement. Central venous catheters play an essential role in enabling vascular access for outpatient and home hemodialysis treatments. This presents new revenue pools for manufacturers as catheter models supporting dialysis on the move gain wider usage. It is expected to widen opportunities in the global central venous catheter market in future.
Link: https://www.coherentmarketinsights.com/market-insight/central-venous-catheter-market-2400
Key Development
- In November 2023, BD , a global medical technology company, announced that it had launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines, and other vascular access devices
- In June 2023, Merit Medical Systems, Inc., a leading global manufacturer and marketer of healthcare technology, announced the acquisition of the Surfacer Inside-Out access catheter system from Bluegrass Vascular Technologies, Inc., the manufacturer of a medical device intended to address limitations in vascular access procedures. The Surfacer is a unique device designed to obtain right-sided central venous access in patients with venous obstructions, providing this population with access to life saving therapies including hemodialysis and chemotherapy.
- In August 2022, Teleflex Incorporated, a medical device company, announced that it had been awarded a contract for the supply of Central Venous Access products from Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company.
Key Players: ICU Medical, Inc., B. Braun SE, Becton, Dickinson and Company, Poly Medicure Ltd., Lepu Medical Technology Co., Ltd., Teleflex Incorporated, VOGT Medical, ZOLL Medical Corporation, EETA Surgical, QMD, Kimal, Medtronic, Rex Medical, LLC., Asahi Kasei Corporation, AngioDynamics, Inc., Merit Medical Systems Inc., CorMedix Inc., and Access Vascular, Inc.
